Cellectis’ Shareholders Meeting to be Held on December 22, 2023
November 17 2023 - 4:30PM
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a
clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, announced today that it will hold a general meeting on
December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11
rue Watt, 4th floor, 75013 Paris, France.
The notice of meeting as published today in the
BALO (Bulletin des Annonces Legales Obligatoires), including the
agenda, the text of the resolutions and the terms of participation,
is online on the Cellectis website at the following address:
https://www.cellectis.com/en/investors/general-meetings/
About CellectisCellectis is a
clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies. Cellectis utilizes an allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to make therapeutic gene editing in
hemopoietic stem cells for various diseases. As a clinical-stage
biopharmaceutical company with over 23 years of experience and
expertise in gene editing, Cellectis is developing life-changing
product candidates utilizing TALEN®, its gene editing technology,
and PulseAgile, its pioneering electroporation system to harness
the power of the immune system in order to treat diseases with
unmet medical needs. Cellectis’ headquarters are in Paris, France,
with locations in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and
on Euronext Growth (ticker: ALCLS).
For further information on Cellectis, please
contact:
Media contact: Patricia Sosa
Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,
media@cellectis.com
Investor Relations contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.comAshley R. Robinson, LifeSci Advisors, +1 617
430 7577
- 20231117- PR-Shareholders-meeting-announcement-ENGLISH.pdf
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Oct 2023 to Oct 2024